Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track SCLX with free AI briefings, catalyst countdowns, and dilution alerts.

SCLX · Scilex Holding Co

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$581,000 Cash on Hand

0.4mo Cash Runway

Follow SCLX by email Get an email when SCLX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SCLX, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

May 2023 · Phase 2 · Results Expected · Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain
Registry primary completion date, not a results date
Apr 2022 · Phase 1 · Results Expected · Pharmacokinetics of SP-104
Registry primary completion date, not a results date
Dec 2021 · Phase 1 · Results Expected · Study to Evaluate the Safety of SP-104
Registry primary completion date, not a results date
Aug 2021 · Phase 3 · Results Expected · Corticosteroid Lumbar Epidural Analgesia for Radiculopathy
Registry primary completion date, not a results date
Jul 2021 · Phase 1 · Results Expected · Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic
Registry primary completion date, not a results date
Aug 2019 · Phase 1 · Results Expected · Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Lidocaine FDA approved Feb 2018 · Ztlido	Healthy	Phase 1 · NCT04150536	Completed
Lidocaine Patch	Neck Pain	N/A · NCT04378959	Completed
Lidocaine 1.8%	Carpal Tunnel Syndrome	Phase 4 · NCT04245371	Completed
SP-102	Lumbosacral Radicular Pain	Phase 3 · NCT03372161	Completed
SP-103	Moderate to Severe Acute Lower Back Pain	Phase 2 · NCT05096494	Completed
ZTlido (Lidocaine Topical System) 1.8%	Healthy	Phase 1 · NCT05106400	Completed
Dronabinol (SP-104)	Healthy	Phase 1 · NCT05002946	Completed
Salonpas (Lidocaine Patch 4%)	Healthy	Phase 1 · NCT05106400	Completed
Naltrexone immediate release oral capsul	Healthy Volunteers	Phase 1 · NCT04958876	Completed
Lidocaine patch 1.8%	Healthy	Phase 1 · NCT04144192	Completed
Lidocaine medicated plaster 5%	Healthy	Phase 1 · NCT04320173	Completed
Lidocaine 2% Injectable Solution	Healthy	Phase 1 · NCT04144192	Completed
IcyHot (Lidocaine 4% + Menthol 1% Patch)	Healthy	Phase 1 · NCT05106400	Completed

Also used in these trials (approved or third-party drugs, not SCLX's own candidates): Naltrexone Hydrochloride, Lidocaine Patch 5%, Lidocaine 5%.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SCLX holds $581,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $3.9M/quarter from operations, an estimated runway of 0.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 37 · Moderate

Cash runway 0 months +40
Share count +22% in a year +7
Raised after last reported balance sheet (Jul 2026) -10

Recent financing filings on SEC EDGAR:

Jul 6, 2026 · Private placement (8-K Item 3.02) · 8-K
Jun 29, 2026 · Private placement (8-K Item 3.02) · 8-K
Feb 20, 2026 · Private placement (8-K Item 3.02) · 8-K
Nov 24, 2025 · Private placement (8-K Item 3.02) · 8-K
Oct 1, 2025 · Private placement (8-K Item 3.02) · 8-K
Sep 26, 2025 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SCLX files for a raise →

Get the full SCLX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCLX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z